MADCAM1 encodes a crucial cell adhesion molecule that directs lymphocyte trafficking to mucosal tissues by serving as a receptor for both α4β7 integrin and L-selectin. The protein plays a fundamental role in immune surveillance by facilitating leukocyte entry into intestinal tissues, including Peyer patches and lamina propria 1. MADCAM1 functions as part of a gut immune checkpoint, where its interaction with α4β7 integrin regulates the migration of regulatory T cells between intestinal and extraintestinal sites 1. In inflammatory bowel disease, targeting the α4β7-MADCAM1 axis with vedolizumab therapy leads to gut-associated lymphoid tissue attrition and reduced intestinal immune cell populations 2. The protein also facilitates thymic T cell progenitor homing to intestines through somatostatin-induced binding 3. Clinically, soluble MADCAM1 levels serve as prognostic biomarkers, with low serum levels correlating with poor outcomes in multiple cancer types 1. MADCAM1 is aberrantly expressed in extraintestinal tissues during inflammatory conditions, such as in portal tract vasculature in IBD-associated primary sclerosing cholangitis 4. The MADCAM1-α4β7 pathway represents a promising therapeutic target for both inflammatory diseases and cancer immunotherapy.